TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of KAN-101 in Celiac Disease (ACeD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Adults aged 18 to 70 years inclusive~2. Diagnosed with celiac disease based on positive serology (eg, tissue transglutaminase IgA antibody and/or deamidated gliadin peptide IgG) and intestinal histology consistent with ≥ Marsh Type II or with evidence of villous atrophy~3. Has HLA-DQ2.5 genotype (HLA-DQA1\*05 and HLA-DQB1\*02) (homozygotes or heterozygotes)~4. Has followed a GFD for \> 12 months immediately prior to study entry~5. Negative or weak positive for tTG-IgA and negative or weak positive for DGP-IgA/IgG during screening~6. Male or female. Females of childbearing potential must use at least 2 acceptable birth control methods~7. Capable of understanding and complying with protocol requirements~8. Patient understands and has signed the informed consent form~Key Exclusion Criteria:~1. Refractory celiac disease~2. Selective IgA deficiency~3. Positive for HLA-DQ8 (DQA1\*03, DQB1\*0302)~4. Previous treatment with tolerance-inducing therapies for celiac disease~5. Known wheat allergy~6. Part B only: History of hyperacute or prolonged symptoms following gluten exposure~7. Uncontrolled or significant medical conditions (including active infections or chronic hepatitis) which, in the opinion of the Investigator, preclude participation~8. History of dermatitis herpetiformis~9. Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- SAD Cohort 1 (Type: EXPERIMENTAL): All enrolled patients will receive one dose of KAN-101 Dose A
- SAD Cohort 2 (Type: EXPERIMENTAL): All enrolled patients will receive one dose of KAN-101 Dose B
- SAD Cohort 3 (Type: EXPERIMENTAL): All enrolled patients will receive one dose of KAN-101 Dose C
- SAD Cohort 4 (Type: EXPERIMENTAL): All enrolled patients will receive one dose of KAN-101 Dose D
- MAD Cohort 5 (Type: EXPERIMENTAL): All randomized patients will receive 3 doses of either KAN-101 Dose A or placebo
- MAD Cohort 6 (Type: EXPERIMENTAL): All randomized patients will receive 3 doses of either KAN-101 Dose B or placebo
- MAD Cohort 7 (Type: EXPERIMENTAL): All randomized patients will receive 3 doses of either KAN-101 Dose C or placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~To be eligible for inclusion into the study, a patient must meet the following criteria:~* Subject has clinically confirmed diagnosis of active Notalgia Paresthetica;~* Subject has a history of chronic pruritus due to Notalgia Paresthetica;~* Subject has moderate to severe pruritus;~* Female subject is not pregnant or nursing during any period of the study.~Key Exclusion Criteria:~A patient will be excluded from the study if any of the following criteria are met:~* Subject has pruritus attributed to a cause other than Notalgia Paresthetica;~* Subject has any clinically significant medical condition or physical/laboratory/ECG/vital signs abnormality that would, in the opinion of the investigator, put the subject at undue risk or interfere with interpretation of study results.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Difelikefalin 2.0 mg (Type: ACTIVE_COMPARATOR): Oral difelikefalin 2.0 mg tablet administered twice daily
- Placebo (Type: PLACEBO_COMPARATOR): Oral placebo tablet administered twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Isotonic Solution Administration Logistical Testing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admitted to the adult medical intensive care unit (MICU) at Vanderbilt University Medical Center~Exclusion Criteria:~* Age\<18 years old

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 0.9% sodium chloride (Type: ACTIVE_COMPARATOR): Participants in the '0.9% sodium chloride' arm will receive 0.9% sodium chloride ('normal saline') any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission.
- Physiologically balanced fluid (Type: ACTIVE_COMPARATOR): Participants in the 'physiologically balanced fluid' arm will receive physiologically balanced fluid (Lactated ringers or Plasmalyte-A) any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ologen (OculusGen)-Phacotrabeculectomy Historical Control Study in India

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Subject inclusion criteria:~1. Age 18 years or over.~2. At least one eye diagnosed with glaucoma and receiving maximally tolerated medical therapy.~3. Visually significant cataract with visual acuity of less than or equal to 6/12.~4. Subject able and willing to cooperate with investigation plan.~5. Subject willing to sign informed consent form.~Subject exclusion criteria:~1. Known allergic reaction to collagen.~2. Subject is on Warfarin and discontinuation is not recommended.~3. Subject with normal tension glaucoma or aphakic glaucoma.~4. Subject with corneal disease.~5. Participation in an investigational study during the 30 days proceeding phacotrabeculectomy.~6. Ocular infection within 14 days prior to phacotrabeculectomy.~7. Pregnant or breast-feeding women.~8. Monocular subject.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OculusGen Collagen Matrix (Type: None): OculusGen Biodegradable Collagen Matrix Implant in Trabeculectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Short Duration High Intensity Intrapleural Alteplase With Pulmozyme in Pleural Infection Management

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patient with age more than 17 year old~* evidence of complex parapneumonic effusion or empyema; with poor pleural fluid drainage of ≤150 mL after 24 hours of insertion of chest drain~* clinical evidence of infection such as fever and or elevated C-reactive protein (CRP) or white-cell count~* complex pleural effusion proven by ultrasound~* pleural fluid analysis that fulfilled at least one of the characteristics: frank pus, exudative nature (according to light's criteria), gram stain or culture positive, lactate dehydrogenase (LDH) \> 1000 U/L, pH \< 7.2 and/or glucose level \< 3.3mmol/L~Exclusion Criteria:~* known allergy to pulmozyme or alteplase~* acute stroke, active bleeding diathesis~* major surgery in past 5 days~* previous pneumonectomy on the infected side~* bronchopleural fistula~* pregnancy~* coagulopathy (INR \> 2, APTT \>100, platelet count \< 50,000 cells)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg for total 3 doses within 24 hours~Intervention Drug: Combination Alteplase and pulmozyme (DNase)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must sign an Informed Consent Form~* In remission from past HE~* Appropriate birth control measures~* More than or equal to 18 years of age~* Must be potential for benefit from treatment~* Recent HE episodes~* Capable and willing to comply with all study procedures~* Participant has support network~Exclusion Criteria:~* Significant medical conditions or Investigator decision not to include the participant~* Allergies to the study drug or similar drugs~* Laboratory abnormalities~* Recent participation in another clinical trial~* Problems experienced in a previous HE trial~* Pregnant or at risk of pregnancy~* Recent alcohol consumption~* Active or latent bacterial or viral Infections~* Bowel issues~* Recent Active Cancer~* On a prohibited medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rifaximin (Type: EXPERIMENTAL): Participants from a previous rifaximin HE study and new participants were administered a single rifaximin 550 milligram (mg) tablet 2 times per day (approximately every 12 hours) for at least 24 months, until regulatory approval of rifaximin for reduction in risk of overt HE recurrence, or until the sponsor closed the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RCT of Misoprostol for Postpartum Hemorrhage in India

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Gestational age equal to or greater than 28 weeks pregnant~* Planning to deliver at home or at a sub-center in the Belgaum District, Karnataka India~* Anticipating a spontaneous vaginal delivery~* Ability and willingness to provide informed consent~Exclusion Criteria:~* Previous caesarian section~* Scheduled for caesarian section~* Hemoglobin level less than 8 Gms%~* Episodes of antepartum bleeding during the current pregnancy~* Blood pressure more than 140 mm of Hg systolic and 90 mm of Hg diastolic~* In active labor and not previously screened, recruited, and consented~* Absence of fetal heart sounds~* Multiple pregnancy~* Known history of bronchial asthma~* Prior enrollment in this study during a previous pregnancy~* History of complications (ante/postpartum hemorrhage/retained placenta/ acute inversion of uterus) during a previous pregnancy~* High risk conditions including: diabetes, cardiac ailments, seizures, placenta previa or anticipated breech delivery.~* Receiving injectable medicine at time of delivery

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Physiological Effects of New Polyphenol-enriched Foods in Humans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* 18 - 45 years old, male and female~* Healthy by medical assessment~* Normal weight: BMI 18 - 25~* Sign of a written informed consent~Exclusion Criteria:~* Age \> 18 and \< 45 years old~* Pregnancy or breastfeeding~* Intestinal or metabolic diseases/disorders such as diabetic, renal, hepatic, hypertension, pancreatic or ulcer, including lactose-intolerance~* Previous abdominal/gastrointestinal surgery~* Regular consumption of medication~* Antibiotic therapy within 2 months previous the study~* Food allergies and intolerances (celiac disease, lactose intolerance, nut allergy etc)~* Unwilling to consume experimental foods~* Concurrent participation or having participated to another clinical trial during the last 3 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- encapsulated curcumin (Type: EXPERIMENTAL): None
- encapsulated curcumin + PQG (Type: EXPERIMENTAL): PQG means Piperine, Quercetin and Genistein
- free cocoa polyphenol (Type: ACTIVE_COMPARATOR): None
- control (Type: PLACEBO_COMPARATOR): None
- encapsulated cocoa polyphenols (Type: EXPERIMENTAL): None
- free curcumin (Type: ACTIVE_COMPARATOR): Subjects will consume bread added with free curcumin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age greater than or equal to 18 years at the time of signing informed consent~* Body mass index greater than or equal to 30 kg/sqm or greater than or equal to 27 kg/sqm with the presence of at least one of the following weight related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease~* History of at least one self-reported unsuccessful dietary effort to lose body weight~Exclusion Criteria:~* Haemoglobin A1c greater than or equal to 48 mmol/mol (6.5%) as measured by central laboratory at screening~* A self-reported change in body weight more than 5 kg (11 lbs) within 90 days before screening irrespective of medical records

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide (Type: EXPERIMENTAL): Run-in Period: Participants will receive semaglutide at an escalating doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) for 20 weeks (week 0 to week 20). The dose will be escalated to next level every 4 weeks.~Maintenance period: Participants will be randomized to receive semaglutide injection for 48 weeks (from week 20 to week 68).~The trial product will be administered as an adjunct to a reduced-calorie diet and increased physical activity during the trial period.
- Placebo (Type: PLACEBO_COMPARATOR): Run-in Period: Participants will receive semaglutide at an escalating doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) for 20 weeks (week 0 to week 20). The dose will be escalated to next level every 4 weeks.~Maintenance period: Participants will be randomized to receive semaglutide placebo injection for 48 weeks (from week 20 to week 68).~The trial product will be administered as an adjunct to a reduced-calorie diet and increased physical activity during the trial period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~•≥ 18 and ≤ 70 years of age~* Histological or cytological confirmed solid malignant tumor~* ECOG performance status of 0-2~* Standard regimen failed or no standard regimen available~* Life expectancy of more than 12 weeks~* LVEF ≥ 50%~Exclusion Criteria:~* Pregnant or lactating women~* Adequate hepatic, renal, heart, and hematologic functions (platelets \<75 × 109/L, neutrophil \<1.5 × 109/L, hemoglobin \< 90g/dl ,serum creatinine within upper limit of normal(ULN), total bilirubin and serum transaminase within upper limit of normal(ULN), and PT, APTT, TT, Fbg normal~* Any factors that influence the usage of oral administration~* Evidence of uncontrolled CNS metastasis~* Intercurrence with one of the following: non-controlled hypertension, coronary artery disease, arrhythmia and heart failure~* Abuse of alcohol or drugs~* Less than 4 weeks from the last clinical trial~* Previous treatment with VEGF/VEGFR inhibition~* Disability of serious uncontrolled intercurrence infection~* Uncontrolled hemorrhage in GI~* Within 12 months before the first treatment occurs artery/venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack) etc.~* Within 6 months before the first treatment occurs acute myocardial infarction, acute coronary syndrome or CABG~* Bone fracture or wounds that was not cured for a long time~* Coagulation dysfunction, hemorrhagic tendency or receiving anticoagulant therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Sulfatinib capsule (Type: EXPERIMENTAL): cohort 1: Sulfatinib single oral dosing;after 7days,Sulfatinib continuous oral dosing ( once a day) 28days as a cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Acetaminophen Plus Tramadol Hydrochloride (JNS013) in Participants With Chronic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with sustention of chronic pain associated with OA or LBP for at least 3 months~* Participants whose pain cannot be controlled sufficiently with at least 14-day continuous treatment with identical oral NSAIDs at a usual maximum dose during 3 months prior to this study~* Outpatients~* Ambulatory participants without need for any supportive device or assistance during daily life~Exclusion Criteria:~* Participants with conditions for which opioids are contraindicated~* Participants with conditions for which acetaminophen is contraindicated~* Participants with history of convulsion or the possibility of convulsive seizure~* Participants with concurrent, previous, or possible alcohol dependence, drug dependence, or narcotic addiction~* Pregnant participants or those who may be pregnant, lactating mothers, and participants who wish pregnancy during the study period

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tramadol Hydrochloride Plus Acetaminophen (Open-Label) (Type: EXPERIMENTAL): None
- Tramadol Hydrochloride Plus Acetaminophen (Double Blind) (Type: EXPERIMENTAL): None
- Placebo (Double-Blind) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who meet the diagnostic criteria for schizophrenia according to DSM-IV-TM for at least 1 year before screening~* have a PANSS score of \<120~* have a body mass index (BMI) \>/=15.0 kilogram (kg)/meter (m)2~* and have resided at the same address for at least 30 days~Exclusion Criteria:~* Patients unable to provide their own consent~* have been involuntarily committed to psychiatric hospitalization~* have primary, active DSM-IV-TM diagnosis other than schizophrenia~* who have a DSM-IV-TM diagnosis of active substance dependence within 3 months before screening (nicotine and caffeine are not exclusionary)~* have a history of treatment resistance as defined by failure to respond to 2 adequate trials (minimum of 4 weeks at a therapeutic dose) of different antipsychotic medications~* have a history of any severe preexisting gastrointestinal narrowing or inability to swallow the medication whole with water~* have a history of neuroleptic malignant syndrome (NMS)~* are at significant risk of suicidal or violent behavior~* current presence of any significant or unstable medication condition~* treatment with any protocol disallowed therapies~* clinically significant result from screening laboratory or ECG.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): Paliperidone Palmitate 25, 50, 75 or 100 mg eq every 4 wk for up to 24 mo
- 002 (Type: PLACEBO_COMPARATOR): Placebo Placebo every 4 wk up to 24 mo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete